Citadel Advisors
SLRN

Citadel Advisors’s ACELYRIN SLRN Stock Holding History

Citadel Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,600
Closed -$3.95K – 14857
2025
Q1 		$3.95K Buy
1,600
+400
+33% +$951 ﹤0.01% 13927
2024
Q4 		$3.77K Sell
1,200
-16,400
-93% -$79.4K ﹤0.01% 13973
2024
Q3 		$86.8K Buy
17,600
+5,000
+40% +$25.8K ﹤0.01% 11309
2024
Q2 		$55.6K Sell
12,600
-53,800
-81% -$252K ﹤0.01% 11641
2024
Q1 		$448K Buy
66,400
+36,600
+123% +$278K ﹤0.01% 8631
2023
Q4 		$222K Sell
29,800
-27,600
-48% -$236K ﹤0.01% 9736
2023
Q3 		$584K Buy
57,400
+53,700
+1,451% +$1.14M ﹤0.01% 7721
2023
Q2 		$77.3K Buy
+3,700
New +$75.7K ﹤0.01% 11281

Other funds holding SLRN

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's SLRN Position: Q2 2025 in Review

Citadel Advisors sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 176,437 shares — an estimated $436K sold.

Citadel Advisors first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $121M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

  • Citadel Advisors reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 176,437 ACELYRIN shares in Q2 2025, an estimated $436K.
  • Citadel Advisors first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
  • Citadel Advisors's ACELYRIN position peaked at $121M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.